Isatuximab meets primary endpoint in Phase 3 trial

The pivotal Phase 3 trial of isatuximab has met its primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma, developer Sanofi has reported.

Full results will be submitted to an upcoming medical meeting and are anticipated to form the basis of regulatory submissions planned for later this year, Sanofi said.

“We are excited by these results, which represent significant progress in our ambition to extend the lives of multiple myeloma patients,” said John Reed, Head of Research and Development at Sanofi.

“We look forward to engaging with regulatory authorities with the goal of bringing this potential new treatment to patients as quickly as possible.”

Multiple myeloma is the second most common hematologic malignancy, with more than 138,0002 new cases worldwide each year. Multiple myeloma remains incurable in the vast majority of patients, resulting in significant disease burden.

ICARIA-MM, the randomised, multi-centre, open label Phase 3 study, enrolled 307 patients with relapsed/refractory multiple myeloma across 96 centres spanning 24 countries.

All study participants received two or more prior anti-myeloma therapies, including at least two consecutive cycles of lenalidomide and a proteasome inhibitor given alone or in combination.

During the trial, isatuximab was administered through an intravenous infusion at a dose of 10mg/kg once weekly for four weeks, then every other week for 28-day cycles in combination with standard doses of pomalidomide and dexamethasone for the duration of treatment.

The safety profile was evaluated as a secondary endpoint.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Related news

Takeda opens R&D cell therapy manufacturing facility

Takeda is expanding its cell therapy manufacturing capabilities with the opening of a new 24,000 sq ft cell therapy manufacturing facility at its R&D...

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...